Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents

Abstract

The use of OKT-3 or alemtuzumab for in vivo T-cell depletion is associated with an increased risk of viral encephalitis after allogeneic stem cell transplantation. Different viruses are frequently associated with distinct characteristics such as onset time, response to treatment and outcome.